Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

[New Brunswick] expands the use of biosimilars to improve the sustainability of public drug plans

The provincial government is improving the sustainability of its public drug plans by expanding the use of biosimilars. In consultation with their physicians, about 3,000 beneficiaries of the province’s drug plans who are living with diseases such as inflammatory arthritis, inflammatory bowel disease, diabetes and psoriasis will have until Nov. 30 to switch from an originator biologic to the biosimilar version. 

Read more

New Brunswick Becomes Third Province in Canada to Implement Biosimilar Switching Policy

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of New Brunswick for implementing a biosimilar “switching” or transitioning policy to expand the use of biosimilar medicines under the province’s public drug plans.
Read more

British Columbia switches from Humira to 5 biosimilar versions

Coverage by The Center for Biosimilars of the adalimumab phase of the BC’s biosimilars program.

Read more